lbl-024 + toripalimab

LBL-024 + toripalimab is a combination investigational immunotherapeutic regimen for cancer composed of LBL-024, a first-in-class tetravalent bispecific monoclonal antibody targeting both PD-L1 and the co-stimulatory receptor 4-1BB (CD137), and toripalimab, a monoclonal antibody targeting PD-1. LBL-024 acts by **blocking the PD-1/PD-L1 immunosuppressive pathway** and **inducing conditional co-stimulation of 4-1BB in the tumor microenvironment**, thereby enhancing T-cell activation and anti-tumor immune responses. Toripalimab is a **PD-1 inhibitor** that prevents immune checkpoint-mediated suppression of T lymphocytes, facilitating improved anti-tumor immunity. This combination leverages dual checkpoint blockade plus co-stimulation, aiming to synergistically boost anti-tumor activity, especially in indications where immune escape is prominent. LBL-024 has shown robust efficacy as monotherapy and in combination, notably in extrapulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and other advanced malignancies[1][3][5][6][7].

Other names

LBL-024LBL024LBL 024